华夏国证疫苗与生物科技指数发起C(016356)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
-1,018,668.02 |
-27,059,395.00 |
-31,448,192.87 |
-19,221,544.08 |
| 利息合计 |
7,877.36 |
18,984.43 |
10,466.66 |
29,893.29 |
| 其中：存款利息收入 |
7,877.36 |
18,984.43 |
10,466.66 |
29,893.29 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-3,838,358.88 |
-20,225,508.72 |
-11,638,342.92 |
-5,712,757.60 |
| 其中：股票投资收益 |
-4,246,090.94 |
-21,436,843.41 |
-12,243,731.78 |
-6,993,028.59 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
407,732.06 |
1,211,334.69 |
605,388.86 |
1,280,270.99 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
2,793,418.56 |
-6,915,147.60 |
-19,837,107.07 |
-13,601,446.75 |
| 其他收入 |
18,394.94 |
62,276.89 |
16,790.46 |
62,766.98 |
| 费用 |
331,197.72 |
754,707.23 |
420,779.03 |
1,183,853.94 |
| 管理人报酬 |
178,216.91 |
387,477.40 |
211,718.12 |
621,636.28 |
| 基金托管费 |
35,643.41 |
77,495.48 |
42,343.66 |
124,327.40 |
| 销售服务费 |
66,184.88 |
146,619.35 |
82,051.89 |
267,685.26 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
51,152.52 |
143,115.00 |
84,665.36 |
170,205.00 |
| 利润总额 |
-1,349,865.74 |
-27,814,102.23 |
-31,868,971.90 |
-20,405,398.02 |
微信公众号
证券之星APP
基本资料
